stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) Gross margin
Recursion Pharmaceuticals, Inc.'s gross margin over the twelve months to 30 September 2026 was 29.2%, up 24.2 percentage points from fiscal 2025 (4.99%). Over the past ten years it has ranged from −22.1% (fiscal 2022) to 100.0% (fiscal 2021); the current reading is higher than 55% of that period. That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 4.99% | (18.13) |
| FY2024 | 23.1% | 18.66 |
| FY2023 | 4.46% | 25.62 |
| FY2022 | −21.2% | 0.95 |
| FY2022 | −22.1% | (122.11) |
| FY2021 | 100.0% | 89.45 |
| FY2021 | 10.6% | (89.45) |
| FY2020 | 100.0% | 100.00 |
| FY2020 | 0.00% | (100.00) |
| FY2019 | 100.0% | 100.00 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 45.9% | 95.67 |
| Jun 2026 | −49.8% | 43.17 |
| Mar 2026 | −93.0% | (152.82) |
| Dec 2025 | 59.8% | 243.64 |
| 23 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| CLDX Celldex Therapeutics, Inc. compare | 100.0% |
| PVLA Palvella Therapeutics, Inc. compare | 100.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | 100.0% |
| VCEL Vericel Corporation compare | 74.5% |
| ADMA ADMA Biologics Inc compare | 68.5% |
| RXRX Recursion Pharmaceuticals, Inc. | 29.2% |
| BHVN Biohaven Ltd. compare | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| MBX MBX Biosciences, Inc. compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on RXRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement